Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-18.79%
0%
-18.79%
6 Months
-60.32%
0%
-60.32%
1 Year
95.15%
0%
95.15%
2 Years
-23.76%
0%
-23.76%
3 Years
-73.48%
0%
-73.48%
4 Years
-94.61%
0%
-94.61%
5 Years
-95.89%
0%
-95.89%
Poxel SA for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
4.41%
EBIT Growth (5y)
13.47%
EBIT to Interest (avg)
-11.51
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.90
Sales to Capital Employed (avg)
1.15
Tax Ratio
1.90%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
1.30%
ROCE (avg)
0
ROE (avg)
0.19%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-0.44
EV to EBIT
-7.13
EV to EBITDA
-7.42
EV to Capital Employed
-13.83
EV to Sales
30.99
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bullish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Dec'23
Dec'23
Dec'22
Change(%)
Net Sales
2.00
0.70
185.71%
Operating Profit (PBDIT) excl Other Income
0.00
-22.80
100.00%
Interest
0.00
4.30
-100.00%
Exceptional Items
0.00
-1.40
100.00%
Consolidate Net Profit
0.00
-31.40
100.00%
Operating Profit Margin (Excl OI)
0.00%
-34,698.80%
3,469.88%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2023 is 185.71% vs -94.78% in Dec 2022
Consolidated Net Profit
YoY Growth in year ended Dec 2023 is 100.00% vs -31.93% in Dec 2022
About Poxel SA 
Poxel SA
Pharmaceuticals & Biotechnology
Poxel SAS is a France-based company principally engaged in the biopharmaceutical sector. The Company develops drugs with a focus on Type 2 diabetes. The Company aims at developing drugs from preclinical to phase 2 clinical proof of concept. Its lead product, Imeglimin, is in clinical phase 2 study for Type 2 diabetes indication. A direct activator of AMPK for the treatment of Type 2 diabetes has started its preclinical development, and other projects in the research phase target diabetes and other metabolic diseases with small molecules that have a disease-modifying mechanism of action. Poxel SAS was spun out from Merck Serono. The Company cooperates with the Laboratory for Fundamental and Applied Bioenergetics, Sumitomo Dainippon Pharma, Joseph Fourier University and Department of Cell Physiology and Metabolism at the University of Geneva, Switzerland, among others.
Company Coordinates 
Company Details
Imm Le Sunway, 259/261 Avenue Jean Jaures LYON None : 69007
Registrar Details






